ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
ImmunoPrecise Antibodies (NASDAQ: IPA) announces significant progress in rabbit monoclonal antibody development using its proprietary B Cell Select® platform. The company's technology has been instrumental in advancing two novel antibodies, OR502 and OR641, for OncoResponse Inc. into clinical trials for cancer treatment.
OR502, targeting LILRB2, has entered Phase I/II trials for advanced solid tumors, showing an excellent safety profile. OR641, a dual antagonist targeting LILRB1 and LILRB2, is undergoing IND-enabling studies. Both antibodies have demonstrated superior ability to reverse immunosuppression in preclinical models.
IPA's B Cell Select® platform has been used in over 200 antibody programs, consistently delivering high-quality therapeutic candidates. The company is now offering more complex therapeutic rabbit antibody campaigns as a partnering model, reinforcing its position in the rapidly advancing field of rabbit monoclonal antibody therapeutics.
ImmunoPrecise Antibodies (NASDAQ: IPA) annuncia progressi significativi nello sviluppo di anticorpi monoclonali di coniglio utilizzando la sua piattaforma proprietaria B Cell Select®. La tecnologia dell'azienda è stata fondamentale nell'avanzamento di due nuovi anticorpi, OR502 e OR641, per OncoResponse Inc. verso le sperimentazioni cliniche per il trattamento del cancro.
OR502, che colpisce LILRB2, è entrato negli studi di Fase I/II per tumori solidi avanzati, mostrando un eccellente profilo di sicurezza. OR641, un antagonista duale che colpisce LILRB1 e LILRB2, è attualmente in fase di studi abilitanti IND. Entrambi gli anticorpi hanno dimostrato una superiore capacità di invertire l'immunosoppressione in modelli preclinici.
La piattaforma B Cell Select® di IPA è stata utilizzata in oltre 200 programmi di anticorpi, fornendo costantemente candidati terapeutici di alta qualità. L'azienda sta ora offrendo campagne di anticorpi terapeutici di coniglio più complesse come modello di partnership, rafforzando la sua posizione nel campo in rapida evoluzione delle terapie con anticorpi monoclonali di coniglio.
ImmunoPrecise Antibodies (NASDAQ: IPA) anuncia avances significativos en el desarrollo de anticuerpos monoclonales de conejo utilizando su plataforma propietaria B Cell Select®. La tecnología de la compañía ha sido fundamental para avanzar en dos anticuerpos novel, OR502 y OR641, para OncoResponse Inc. hacia ensayos clínicos para el tratamiento del cáncer.
OR502, que se dirige a LILRB2, ha entrado en ensayos de Fase I/II para tumores sólidos avanzados, mostrando un excelente perfil de seguridad. OR641, un antagonista dual que se dirige a LILRB1 y LILRB2, está en estudios que habilitan IND. Ambos anticuerpos han demostrado una capacidad superior para revertir la inmunosupresión en modelos preclínicos.
La plataforma B Cell Select® de IPA se ha utilizado en más de 200 programas de anticuerpos, proporcionando consistentemente candidatos terapéuticos de alta calidad. La compañía ahora está ofreciendo campañas de anticuerpos terapéuticos de conejo más complejas como modelo de asociación, reforzando su posición en el campo en rápida evolución de las terapias con anticuerpos monoclonales de conejo.
ImmunoPrecise Antibodies (NASDAQ: IPA)는 자사의 독자적인 B Cell Select® 플랫폼을 이용하여 토끼 단클론 항체 개발에서 중요한 진전을 알렸습니다. 이 회사의 기술은 OncoResponse Inc.를 위한 두 가지 새로운 항체, OR502 및 OR641의 임상 시험을 진행하는 데 중요한 역할을 했습니다.
OR502는 LILRB2를 타겟으로 하여 고급 고형 종양에 대한 1/2상 시험에 들어갔으며, 훌륭한 안전성 프로파일을 보여주고 있습니다. OR641는 LILRB1과 LILRB2를 타겟으로 하는 이중 길항제로 IND 승인 연구가 진행 중입니다. 두 항체 모두 전임상 모델에서 면역억제를 회복시키는 뛰어난 능력을 입증했습니다.
IPA의 B Cell Select® 플랫폼은 200개 이상의 항체 프로그램에서 사용되었으며, 일관되게 고품질의 치료 후보 물질을 제공합니다. 회사는 이제 더 복잡한 치료용 토끼 항체 캠페인을 파트너십 모델로 제공하고 있으며, 빠르게 발전하는 토끼 단클론 항체 치료 분야에서의 위상을 강화하고 있습니다.
ImmunoPrecise Antibodies (NASDAQ: IPA) annonce des progrès significatifs dans le développement d'anticorps monoclonaux de lapin utilisant sa plateforme propriétaire B Cell Select®. La technologie de l'entreprise a été essentielle à l'avancement de deux anticorps novateurs, OR502 et OR641, pour OncoResponse Inc. vers des essais cliniques pour le traitement du cancer.
OR502, ciblant LILRB2, a entamé des essais de Phase I/II pour des tumeurs solides avancées, montrant un excellent profil de sécurité. OR641, un antagoniste dual ciblant LILRB1 et LILRB2, est en cours d'études IND. Les deux anticorps ont démontré une capacité supérieure à inverser l'immunosuppression dans des modèles précliniques.
La plateforme B Cell Select® d'IPA a été utilisée dans plus de 200 programmes d'anticorps, fournissant régulièrement des candidats thérapeutiques de haute qualité. L'entreprise propose désormais des campagnes d'anticorps thérapeutiques de lapin plus complexes comme modèle de partenariat, renforçant ainsi sa position dans le domaine en évolution rapide des thérapies à base d'anticorps monoclonaux de lapin.
ImmunoPrecise Antibodies (NASDAQ: IPA) kündigt bedeutende Fortschritte in der Entwicklung von monoklonalen Kaninchenantikörpern unter Verwendung seiner proprietären B Cell Select®-Plattform an. Die Technologie des Unternehmens war entscheidend für den Fortschritt von zwei neuartigen Antikörpern, OR502 und OR641, für OncoResponse Inc. in klinische Studien zur Krebsbehandlung.
OR502, das auf LILRB2 abzielt, hat Phase I/II-Studien zu fortgeschrittenen soliden Tumoren betreten und zeigt ein ausgezeichnetes Sicherheitsprofil. OR641, ein dualer Antagonist, der LILRB1 und LILRB2 anspricht, befindet sich in IND-auslösenden Studien. Beide Antikörper haben eine überlegene Fähigkeit zur Umkehrung der Immunsuppression in präklinischen Modellen gezeigt.
Die B Cell Select®-Plattform von IPA wurde in mehr als 200 Antikörperprogrammen eingesetzt und liefert konstant hochwertige therapeutische Kandidaten. Das Unternehmen bietet nun komplexere therapeutische Kaninchenantikörper-Kampagnen als Partnering-Modell an und festigt damit seine Position im sich schnell entwickelnden Bereich der therapeutischen monoklonalen Kaninchenantikörper.
- Two novel antibodies (OR502 and OR641) developed using IPA's B Cell Select® platform have advanced to clinical trials
- OR502 has entered Phase I/II clinical trials with an excellent safety profile
- OR641 has completed Cell Line Development and is undergoing IND-enabling studies
- IPA's B Cell Select® platform has been used in over 200 antibody programs
- IPA is offering more complex therapeutic rabbit antibody campaigns as a partnering model
- None.
Insights
ImmunoPrecise Antibodies (IPA) has made significant strides in rabbit monoclonal antibody development, showcasing the potential of their B Cell Select® platform. The clinical progress of OncoResponse's OR502 and OR641 antibodies, both discovered using IPA's technology, is particularly noteworthy:
- OR502 has entered Phase I/II trials for advanced solid tumors, demonstrating safety and potential efficacy.
- OR641 is undergoing IND-enabling studies, showing promise in reversing immunosuppression.
These developments highlight IPA's growing influence in the $150 billion monoclonal antibody market. The company's ability to rapidly design and advance antibodies to clinical stages for multiple clients strengthens its position as a leading Contract Research Organization.
The rabbit antibody platform's success in over 200 programs across various targets demonstrates IPA's technological edge. This could lead to increased demand for IPA's services and potential licensing opportunities. However, investors should note that clinical success doesn't guarantee market approval or commercial viability.
While this news is positive for IPA's long-term prospects, the immediate financial impact may be The company's
The clinical progress of OR502 and OR641 represents a significant advancement in cancer immunotherapy. These antibodies target LILRB2 and LILRB1/2, respectively, which are important immune checkpoint molecules:
- OR502's entry into Phase I/II trials for advanced solid tumors is promising, especially given its safety profile and potential to reverse myeloid cell-mediated immunosuppression.
- OR641's dual targeting of LILRB1 and LILRB2 could offer a more comprehensive approach to overcoming tumor immune evasion.
The preclinical data suggesting superior efficacy compared to other anti-LILRB antibodies is particularly intriguing. If these results translate to clinical settings, it could represent a significant leap forward in treating immunosuppressive tumors.
However, it's important to temper enthusiasm with caution. Many promising preclinical candidates fail to show efficacy in human trials. The true test will be in the upcoming clinical results, especially for OR502's Phase I/II trial.
For IPA, this progress validates their platform's capability to produce clinically relevant antibodies, potentially attracting more partnerships and investment in their technology.
Rabbit B Cell Select® Drives Clinical Breakthroughs in Cancer Treatment
OncoResponse’s Breakthrough in Cancer Treatment
In a live presentation at the recent PEGS 2024 conference, OncoResponse shared exciting updates on two novel antibodies, OR502 and OR641, both of which were discovered and refined using IPA’s innovative B Cell Select® platform:
- OR502, a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody, has successfully entered Phase I/II clinical trials, showing excellent safety profile, and is being evaluated for efficacy in treating advanced solid tumors. Preclinical models have demonstrated that OR502 is a best-in-class anti-LILRB2 antibody that reverses immunosuppression caused by myeloid cells in the TME.
- OR641, a novel, humanized dual antagonist antibody targeting both LILRB1 and LILRB2, has completed Cell Line Development and is undergoing IND-enabling studies. Preclinical models have demonstrated its superior ability to reverse immunosuppression caused by myeloid and lymphoid cells compared to other anti-LILRB1/2 antibodies.
Driving Antibody Discovery and Design for Clinical Success
IPA’s proprietary B Cell Select® platform has been instrumental in the rapid design and discovery of antibodies that have advanced to clinical stages for numerous clients. By preserving the natural structure of antibodies, IPA’s technology supports optimal functioning of the therapies in a clinical setting. Through comprehensive testing and validation, the process ensures that these antibodies maintain their efficacy and reliability from the lab to the clinic.
"At ImmunoPrecise Antibodies, our mission is not just to develop antibodies, but to redefine what’s possible in therapeutic interventions," said Dr. Jennifer Bath, President and CEO of IPA. "Our innovative platform, built on years of expertise, has consistently delivered antibodies with superior qualities, many of which are now advancing in clinical trials. This reflects our unwavering commitment to innovation and our strategic advantage in the market. We are proud to support our clients in bringing groundbreaking, life-changing treatments to patients around the world, reinforcing the long-term value of our technologies."
Harnessing Rabbit B Cell Technology for Breakthrough Antibody Discovery
The Rabbit B Cell platform, a rapidly advancing technology in therapeutic antibody development, played a pivotal role in the discovery process. This platform excels at generating high-affinity and highly specific rabbit monoclonal antibodies, a demand met with very limited providers in the market.
IPA has successfully utilized their B Cell Select platform in over 200 antibody programs, achieving remarkable success against a variety of targets, including small molecules, peptides, and proteins. The distinctive properties of rabbit antibodies, combined with IPA’s expertise, have consistently led to the development of promising therapeutic candidates. Building on this success, IPA is now offering more complex therapeutic rabbit antibody campaigns as a partnering model, providing companies with greater flexibility in structuring their more complicated programs.
Outlook
The field of rabbit monoclonal antibody (mAb) therapeutics is advancing rapidly, driven by innovations in antibody engineering and humanization techniques. These advancements are making rabbit mAbs increasingly popular for human therapeutic use. The unique properties of rabbit antibodies, combined with IPA’s full-service technologies, such as in silico humanization, indicate a strong potential for more rabbit-derived mAbs to enter clinical trials and achieve approval in the coming years. The distinctive advantages of rabbit antibodies make them a promising foundation for future therapeutic development. As this technology progresses, IPA remains at the forefront, harnessing these innovations to bring new, effective treatments to the clinic, reinforcing our growing leadership in the industry.
Dr. Kamal D. Puri, Chief Scientific Officer of OncoResponse, recognized IPA’s pivotal role in their success, praising the quality and reliability of IPA’s antibody discovery services. “We are thrilled to have worked with IPA to discover our lead therapeutic antibodies. The IPA team’s deep experience and know-how with a battery of customized, high-throughput discovery strategies has played a critical role in the successful discovery of our molecules with unsurpassed speed and efficiency,” said Kamal D. Puri, Chief Scientific Officer of OncoResponse.
About OR502
LILRB2 is an immunoinhibitory receptor expressed on tumor-associated macrophages (TAMs) found in the tumor microenvironment (TME). TAMs inhibit the activity of checkpoint inhibitor (CPI) therapy and prevent T cells from killing tumors. Blocking the inhibitory activity of TAMs and promoting the activity of tumor-killing T cells reverses inhibition of CPI therapy, potentially leading to more and deeper responses to CPIs in patients. This is the mechanism of OR502, which modulates LILRB2 by blocking its engagement of HLA-G on tumor cells and prevents the suppression of the myeloid cells. Elevated expression of LILRB2 correlates with reduced patient survival in various tumor types. This humanized monoclonal antibody, OR502, targets LILRB2 and blocks the inhibitory activity of TAMs and promotes the activity of tumor-killing T cells, reversing inhibition of CPI therapy.
About OncoResponse
OncoResponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of Elite Cancer Responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel antibodies targeting immune cells in the tumor microenvironment. The company’s lead clinical candidate, OR502 is a best-in-class anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2-mediated immune suppression and has entered clinical study in 2023. OR502 clinical studies are being conducted with support from the Cancer Prevention Research Institute of
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in
Forward-Looking Statement
This news release contains forward-looking statements within the meaning of applicable
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the Company’s Annual Report on Form 20-F for the year ended April 30, 2024 (which may be viewed on the Company’s SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240926217701/en/
Investor Relations Contact
Kirsten Beduya
Quantum Media Group, LLC
kirsten@quantum-corp.com
Source: ImmunoPrecise Antibodies Ltd.
FAQ
What is the current status of OR502, the antibody developed by ImmunoPrecise Antibodies (IPA)?
How many antibody programs has ImmunoPrecise Antibodies (IPA) completed using their B Cell Select® platform?
What new offering is ImmunoPrecise Antibodies (IPA) introducing for therapeutic rabbit antibody campaigns?
What is the target of OR641, the dual antagonist antibody developed by ImmunoPrecise Antibodies (IPA)?
